kimberley-bracelet1680x1120.png

In August, we celebrate a significant milestone with Paspaley reaching $2 million in donations in support of Garvan’s cancer research. 

Paspaley’s jewellery with purpose

antibody-illustration-Garvan-Institute

New insights into how checkpoint inhibitors affect the immune system could improve cancer treatment.

Study reveals cause of common cancer immunotherapy side effect

Brooke_Pereira_Kendelle_Murphy_Garvan_Institute

The projects are targeting the dense scarring around pancreatic tumours that hinders the success of chemotherapy.

Pancreatic cancer projects funded at Garvan to investigate new strategies for therapy

Professor Stuart Tangye and Dr Ira Deveson

Stuart-Tangye-Ira-Deveson-Garvan-Institute

Professor Stuart Tangye and Dr Ira Deveson have been recognised for their outstanding contributions to immunology and clinical genomics.

Garvan researchers honoured with NSW Premier’s Prizes

Professor-Stuart-Tangye-3_Garvan-Institute.jpg

Professor Stuart Tangye’s work advancing rare immune disease research has received national recognition.

Garvan immunologist awarded 2024 Eureka Prize

Professor Daniel MacArthur speaking at SXSW Sydney

SXSW_Daniel_MacArthur_Garvan-Institute.jpg

Researchers aim to collect genetic data from 10,000 diverse Australians to improve disease prediction, diagnosis and treatment for people from under-represented backgrounds.

Diverse Australians invited to shape future of genomic medicine

Dr David Herrmann and Professor Paul Timpson

Paul-Timpson-and-David-Hermann_Garvan-Institute.jpg

A new trial will test whether ‘priming’ pancreatic cancer can make it more susceptible to chemotherapy.

Pancreatic cancer clinical trial to test new approach to treatment

Peter_Croucher_Garvan_Institute

Professor Peter Croucher has been honoured with an award from the American Society for Bone and Mineral Research.

Prestigious bone research award for Professor Peter Croucher

190618_Alex-Swarbrick_Garvan-Institute

Research into predictive biomarkers at Garvan has been recognised internationally with a significant funding boost.

International fellowship for Garvan breast cancer researcher

Liz-Caldon-Garvan-Institute

By analysing more than 80 clinical trials, researchers at Garvan have identified genetic tests that predict which cancer patients are likely to benefit from PARP inhibitors in combination with chemotherapy.

Predicting cancer patient response to PARP inhibitors

Deborah_Burnett_Garvan_Institute

Prestigious fellowship recognises Dr Burnett’s exceptional research in immunology.

L’Oréal-UNESCO Fellowship awarded to Garvan’s Dr Deborah Burnett

Deborah-Burnett.jpg

The 2023 NSW Premier’s Prize for Early Career Researcher of the Year (Biological Sciences) recognises Garvan’s Dr Deborah Burnett.

Dr Deborah Burnett honoured with NSW Premier’s Prize

Professor Paul Timpson and Associate Professor Marina Pajic at the Garvan Institute

Paul-Timpson-Marina-Pajic-Garvan-Institute

Garvan researchers will contribute to multi-institutional collaborations to overcome current challenges in cancer treatment.

Researchers unite for major national cancer projects

Scott_Perkins_Garvan_Chair_Board.jpg

We are pleased to announce the appointment of Mr Scott Perkins as Chair of Garvan's Board of Directors. 

New Chair for Garvan Institute of Medical Research

Ira_Deveson_and_Andre_Reis_Garvan_Institute

New research provides the most comprehensive picture to date of the genomic diversity within and between First Nations communities across Australia.

Unique diversity of Indigenous Australians revealed by next-generation genomics

Dr Joanna Achinger-Kawecka and Dr David Herrmann

Joanna-Achinger-Kawecka_David Herrmann

Garvan researchers investigating the ‘ecosystems’ of breast and pancreatic cancer have been awarded Ideas Grants from the National Health and Medical Research Council.

Innovative cancer research projects awarded NHMRC funding

Professor Susan Clark, Professor Tri Phan, Associate Professor Elissa Deenick and Associate Professor Marina Pajic

Elissa-Deenick-Marina-Pajic-Susan-Clark-Tri-Phan

A significant funding boost will help Garvan’s cancer and immunology researchers pursue new directions and form collaborations.

Personalised medicine research projects backed by major grants

Professor Tri Phan, Dr Jennifer Massey and Associate Professor Elissa Deenick, leaders of the OCCAMS multiple sclerosis research consortium.

Tri-Phan_Jennifer-Massey_Elissa-Deenick_OCCAMS

Researchers and clinicians across Australia unite to develop better ways to detect, prevent and treat multiple sclerosis.

Sydney researchers to lead multiple sclerosis study

Dr Joanna Achinger-Kawecka, Professor Susan Clark and Associate Professor Clare Stirzaker

Composite_photo_.png

Garvan researchers have revealed a reason why endocrine resistance develops in breast cancers and how to potentially treat it in patients.

Epigenetic therapy shows promise for endocrine-resistant breast cancer

Professor Christopher Goodnow and Dr Tim Peters

immunity-break-story_Garvan-Institute-2.jpg

Researchers have identified a new genomic signature that controls whether the immune system’s specialised ‘killer’ T cells activate or stand down, revealing 100 potential new drug targets for cancer and autoimmune disease.

Immune ‘brake’ reveals drug targets for cancer and autoimmune disease

Dr Brooke Pereira (L) and Dr Kendelle Murphy (R)

Brooke-Pereira-and-Kendelle-Murphy_Garvan-Institute.jpeg

CINSW awards Early Career Fellowships to two Garvan cancer researchers.

Cancer Institute NSW funds early career research

220104_Thomas-Cox_Garvan-Institute

Garvan’s Associate Professor Thomas Cox has received funding to investigate a new treatment approach for pancreatic cancer.

A/Prof Thomas Cox awarded NHMRC Development Grant

Professor Mike Rogers and Dr Marcia Munoz

Mike-Rogers-and-Marcia-Munoz_Garvan-Institute.jpeg

Researchers have uncovered a mechanism by which bisphosphonates – a treatment commonly prescribed for osteoporosis – may help fight respiratory infections.

Common osteoporosis medication boosts immune response in lungs

Dr Deborah Burnett at the Garvan Institute

deborah-burnett_Garvan-Institute.jpeg

Dr Deborah Burnett outlines the pros and cons of variant-specific vaccines and the search for a universal COVID vaccine.

Will an Omicron-specific vaccine help control COVID? There’s one key problem

220128_Alex-Swarbrick_Garvan-Institute

Researchers at Garvan have identified a potential therapy that may improve how effectively chemotherapy targets neuroblastomas.

Research reveals approach to improve therapy for childhood cancer

Professor Leslie Burnett AM was among those recognised in the 2022 Australia Day Honours


220131_Leslie-Burnett-AM-Australia-Day-Honours_Garvan-Institute

For significant contributions to science, leadership, philanthropy and the arts.

Garvan community recognised in Australia Day Honours List

Dr Brooke Pereira and Professor Paul Timpson

brooke-Pereira-and-Paul-Timpson_Garvan-Institute.jpeg

PanKind foundation supports new study to improve immunotherapy outcomes in pancreatic cancer.

Funding boost to Garvan’s pancreatic cancer research

220303_Paul-Timpson_Garvan-Institute

A Garvan project to explore a potential new approach to treating fibrosis in breast cancer has been awarded a grant from the US Department of Defense.

US Defense Department backs breast cancer research

ira-deveson-and-kishore-kumar_Garvan-Institute.jpeg

Garvan researchers have shown how new genomic sequencing technology can reduce the 'diagnostic odyssey' experienced by people with rare neurological and neuromuscular diseases.

Single test for over 50 genetic diseases will cut diagnosis from decades to days

Associate Professor David Croucher, Dr Sharissa Latham and Professor Alex Swarbrick

David-Croucher-and-Sharissa-Latham-and-Alex-Swabrick.jpeg

Two teams at the Garvan Institute have been awarded project grants from Cancer Council NSW to explore innovative new frontiers in cancer research.

Cancer Council NSW grants for Garvan researchers

Professor David Thomas at Project Prospect launch at Garvan

220317_David-Thomas-Project-Prospect_Garvan-Institute

The Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) will establish Australia as a medical manufacturing hub: building links from research through to the clinic; creating jobs; changing lives.

$185 million investment to fast-track treatments for rare and ‘untreatable’ cancers

Professor Elgene Lim at the Garvan Institute

220318_Elgene-Lim_Garvan-Institute.jpeg

Cancer Council NSW awards Sally Crossing AM Award

Professor Elgene Lim recognised for outstanding outcomes in cancer research

(L-R) Mr José Alquicira-Hernández, Dr Seyhan Yazar and Professor Joseph Powell

220408_Jose-Alquicira-Hernandez-Seyhan-Yazar-Joseph-Powell_Garvan-Institute

Most autoimmune diseases are easy to diagnose but hard to treat. A paper published today in Science proposes using your unique immune cell fingerprint to rapidly identify which treatments will work for your autoimmune disease.

An immune ‘fingerprint’ reveals path for better treatment of autoimmune diseases

220421_Stuart-Tangye_Garvan-Institute

Identifying a rare genetic mutation that weakens the immune system can better inform those who may be at higher risk of severe viral illness.

Rare genetic mutation linked to risk of severe viral infection in Polynesian populations

220509_Chris-Goodnow_Garvan-Institute

The American Association of Immunologists has awarded Professor Goodnow with the AAI-BioLegend Herzenberg Award

Professor Chris Goodnow, Garvan’s Executive Director, recognised for his outstanding work in immunology

Associate Professor Christine Chaffer and Dr Tatyana Chtanova

Christine-Chaffer-and-Tatyana-Chtanova_Garvan-Institute.jpeg

More than $1.8 million has been awarded to Garvan researchers to fund projects for breast cancer and immune system modelling.

Garvan projects funded for next stages

Professor Tri Phan at the Garvan Institute

9mb-Tri-Phan_Garvan-Institute.jpeg

A new study shows that people can increase their chances of a diagnosis by 10 per cent if they have a follow-up analysis of their genetic test

Follow-up genetic testing gives patients further chance of diagnosis

Joseph-Powell_new.png

Australian researchers uncover hidden genetic markers of glaucoma

Stem-cell models reveal glaucoma secrets

220610_Kate-Patterson_Garvan-Institute.jpeg

Research into visual scientific communication offers new insights into how to design the best visual aids to help teachers teach science.

Refining the teaching tools by creating better scientific animations

220621_Christine-Chaffer_Garvan-Institute.jpeg

Researchers are recruiting volunteers for a clinical trial they hope will improve survival rates for an aggressive form of breast cancer that affects about 1,500 women each year in New South Wales.

Clinical trial to test potential new combination therapy for aggressive breast cancer

Christopher-Goodnow-2020_Garvan-Institute.jpeg

Professor Goodnow  FAA FRS steps down from Executive Directorship for health reasons after four years at the helm but to continue as senior Faculty and head of Hope Research program.

Garvan celebrates Professor Chris Goodnow and his extensive contributions as Executive Director

220713_Anna-Cuomo_Garvan-Institute

Dr Cuomo has been awarded a highly competitive, international two-year fellowship.

Dr Anna Cuomo recognised with EMBO fellowship

Kate Harvey (L) and Professor Sandra O'Toole (R)

Eureka-Prize-Finalists_Garvan-Institute.jpeg

Professor Sandra O’Toole and Kate Harvey are finalists in the 2022 ANSTO Eureka Prize for Innovative Use of Technology.

Garvan researchers selected as Eureka Prize finalists

220926_Daniel-MacArthur_Garvan-Institute

Populations not currently represented in genetic databases will now have inclusion, thanks to support from the Medical Research Future Fund.

More inclusive genomic resource for diverse Australian communities kickstarted with $10M from the Australian Government

220926_Ira-Deveson_Garvan-Institute

New genomics resources to help Indigenous Australians find genetic diagnoses will be established thanks to support from the Medical Research Future Fund.

New genomic database to help boost Indigenous healthcare

221003_susan-clark_Garvan-Institute

The discovery of a new biomarker for prostate cancer could lead to better diagnosis and treatment for men with the aggressive form of this disease.

New epigenetic markers for prostate cancer discovered

221004_Mike-Rogers_Garvan-Institute

Groundbreaking research offers insights into understanding the inflammatory disorder mevalonate kinase deficiency, and reveals new potential treatment approaches for this devastating disease.

Higher body temperature alters key protein in autoinflammatory disorder

221020_Katherine-Samaras_Garvan-Institute

A commonly used treatment for diabetes may hold the key to slowing cognitive decline to prevent dementia. This Phase 3 clinical trial is seeking participants.

Clinical trial will test drug treatment for prevention of dementia

221102_Robert-Weatheritt_Garvan-Institute

Associate Professor Robert Weatheritt has been selected as a Viertel Senior Medical Research Fellow.

Five-year funding for research on new pathways to boost chemotherapy success

221108_Alex-Swarbrick_Garvan-Institute

Using DNA barcodes to track cancer cells through time, Garvan scientists have shown that cells within a cancer have diverse abilities to escape immune system defences.

DNA barcoding reveals cancer cells’ ability to evade the immune system

221118_Sean-Porazinski_Garvan-Institute

PanKind Foundation supports new study to develop tailored therapy for pancreatic cancer.

Accelerator Grant for pancreatic cancer researcher

Dr Amelia Parker and Associate Professor Thomas Cox

221114_Amelia-Parker-and-Thomas-Cox_Garvan-Institute

Molecular profiles of the matrix around non-small cell lung cancers identifies which tumours become aggressive and require more targeted treatment.

Tumour matrix profiling gives clues to progression of some lung cancers

Dr Etienne Masle-Farquhar at the Garvan Institute

Etienne-Masle-Farquhar_Garvan-Institute.jpeg

Scientists have pinpointed rogue immune cells as a major contributor to autoimmune conditions like rheumatoid arthritis and aplastic anaemia.

Rogue immune cells linked to leukaemia are a key driver of autoimmune diseases

CSL-Florey-Jose-Alquicira-Hernandez_Garvan-Institute.jpeg

An early career researcher at the Garvan Institute has been selected by the Australian Institute of Policy and Science as one of three finalists for a prestigious biennial award.

CSL Florey Next Generation Award shortlist recognises a rising star in the field of cellular genomics

221215_Deborah-Burnett_Garvan-Institute

Prestigious national award recognises Dr Deborah Burnett’s outstanding contribution to health and medical innovation.

Garvan researcher wins Highly Commended in the Annual Health and Medical Research Awards

Amelia-Parker_Garvan-Institute.jpeg

Garvan researcher receives Cancer Australia funding to progress lung cancer prediction and treatment.

New avenues for precision medicine in lung cancer research

Professor Jacqueline Center and Dr Dana Bluic at the Garvan Institute

Jacqueline-Center-Dana-Bluic_Garvan-Institute.jpeg

Patients with complex medical conditions at high fracture risk are vastly undertreated for fracture prevention yet at higher risk of further fracture.

Poorer health outcomes for at-risk patients with fractures

230120_Mandy-Ballinger_Garvan-Institute

Australian researchers have created the first genetic map to identify important genes that cause sarcoma, one of the most common cancers in children.

Genes that cause a rare childhood cancer revealed by Australian-led study

230424_Tri-Phan_Garvan-Institute

Children have a strong initial immune reaction to coronavirus, but don’t transfer this to long-lasting memory T cells like adults do, new research shows.

Explore our research

Our impact

Our people

News and resources

About us

Support Us

News

Featured Article

Study reveals cause of common cancer immunotherapy side effect